Immunocore IMCR
$26.41 −$0.22 (-0.83%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.41 0.00%
Open$26.37
Prev close$26.63
Day range$25.61 – $26.82
Volume546.2K
Market cap$1.36B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±3.1%last 9 reports
Closed higher4 of 944% of the time
Best reaction+5.3%
Worst reaction-4.5%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±14.5% | +3.63% | Within range |
| 2025/Q4 | 25 Feb 2026 | Pre Market | ±15.0% | -4.51% | Within range |
| 2025/Q2 | 7 Aug 2025 | Pre Market | ±9.1% | -0.53% | Within range |
| 2024/Q4 | 26 Feb 2025 | Pre Market | ±17.5% | +5.34% | Within range |
| 2024/Q2 | 8 Aug 2024 | Pre Market | ±16.3% | +2.76% | Within range |
| 2023/Q4 | 28 Feb 2024 | Pre Market | ±9.8% | -1.76% | Within range |
| 2023/Q2 | 10 Aug 2023 | Pre Market | ±9.7% | -3.67% | Within range |
| 2022/Q4 | 1 Mar 2023 | Pre Market | ±16.8% | -1.46% | Within range |
| 2022/Q2 | 10 Aug 2022 | Pre Market | – | +4.27% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$102.22M-1.4% YoY
Operating profit-$13.61M-89.8% YoY
Net profit-$14.22M-7,935.0% YoY
Diluted EPS-$0.28
Free cash flow$17.74M+441.0% YoY
Operating cash flow$20.09M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
Return on equity-7.9%
Return on assets-2.9%
Return on invested capital-4.0%
Current ratio4.62
Liabilities / assets62.8%
Cash & investments$901.30M
Total debt$433.97M
Net cash (debt)$467.33M
No comments yet — be the first to weigh in on IMCR.
Sign in to join the discussion.